Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa
- PMID: 17020611
- PMCID: PMC1594577
- DOI: 10.1186/1475-2875-5-82
Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa
Abstract
Background: In vitro and in vivo resistance of Plasmodium falciparum to atovaquone or atovaquone-proguanil hydrochloride combination has been associated to two point mutations in the parasite cytochrome b (cytb) gene (Tyr268Ser and Tyr268Asn). However, little is known about the prevalence of codon-268 mutations in natural populations of P. falciparum without previous exposure to the drug in Africa.
Methods: The prevalence of codon-268 mutations in the cytb gene of African P. falciparum isolates from Nigeria, Malawi and Senegal, where atovaquone-proguanil has not been introduced for treatment of malaria was assessed. Genotyping of the cytb gene in isolates of P. falciparum was performed by PCR-restriction fragment length polymorphism and confirmed by sequencing.
Results: 295 samples from Nigeria (111), Malawi (91) and Senegal (93) were successfully analyzed for detection of either mutant Tyr268Ser or Tyr268Asn. No case of Ser268 or Asn268 was detected in cytb gene of parasites from Malawi or Senegal. However, Asn268 was detected in five out of 111 (4.5%) unexposed P. falciparum isolates from Nigeria. In addition, one out of these five mutant Asn268 isolates showed an additional cytb mutation leading to a Pro266Thr substitution inside the ubiquinone reduction site.
Conclusion: No Tyr268Ser mutation is found in cytb of P. falciparum isolates from Nigeria, Malawi or Senegal. This study reports for the first time cytb Tyr268Asn mutation in unexposed P. falciparum isolates from Nigeria. The emergence in Africa of P. falciparum isolates with cytb Tyr268Asn mutation is a matter of serious concern. Continuous monitoring of atovaquone-proguanil resistant P. falciparum in Africa is warranted for the rational use of this new antimalarial drug, especially in non-immune travelers.
Figures


Similar articles
-
In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand.Malar J. 2008 Jan 28;7:23. doi: 10.1186/1475-2875-7-23. Malar J. 2008. PMID: 18226262 Free PMC article.
-
Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe.J Infect Dis. 2004 Nov 1;190(9):1541-6. doi: 10.1086/424469. Epub 2004 Sep 28. J Infect Dis. 2004. PMID: 15478057
-
Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers.J Antimicrob Chemother. 2006 Jan;57(1):110-5. doi: 10.1093/jac/dki420. Epub 2005 Nov 30. J Antimicrob Chemother. 2006. PMID: 16319183
-
Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.Drugs. 2003;63(6):597-623. doi: 10.2165/00003495-200363060-00006. Drugs. 2003. PMID: 12656656 Review.
-
Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis.J Antimicrob Chemother. 2018 Mar 1;73(3):581-595. doi: 10.1093/jac/dkx431. J Antimicrob Chemother. 2018. PMID: 29237012 Free PMC article.
Cited by
-
Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil.Malar J. 2008 Nov 20;7:240. doi: 10.1186/1475-2875-7-240. Malar J. 2008. PMID: 19021900 Free PMC article.
-
Alkoxycarbonate Ester Prodrugs of Preclinical Drug Candidate ELQ-300 for Prophylaxis and Treatment of Malaria.ACS Infect Dis. 2017 Oct 13;3(10):728-735. doi: 10.1021/acsinfecdis.7b00062. Epub 2017 Sep 27. ACS Infect Dis. 2017. PMID: 28927276 Free PMC article.
-
Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone-proguanil in traveller returning from Congo.Malar J. 2020 Jan 21;19(1):37. doi: 10.1186/s12936-020-3126-y. Malar J. 2020. PMID: 31964401 Free PMC article.
-
A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor.ACS Chem Biol. 2011 Nov 18;6(11):1214-22. doi: 10.1021/cb200105d. Epub 2011 Sep 8. ACS Chem Biol. 2011. PMID: 21866942 Free PMC article.
-
In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand.Malar J. 2008 Jan 28;7:23. doi: 10.1186/1475-2875-7-23. Malar J. 2008. PMID: 18226262 Free PMC article.
References
-
- Milhous WK. Development of new drugs for chemoprophylaxis of malaria. Med Trop (Mars) 2001;61:48–50. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical